People who find it difficult to find time to exercise during a busy work week may concentrate their moderate-to-vigorous physical activity to one to two days of the week or weekend.
Cingulate prepares for FDA approval for its once-daily ADHD pill – Pharmaceutical Technology
Cingulate is planning to initiate two Phase III trials of CTx-1301 for treating ADHD in paediatric and adolescent patient populations in August 2023. Image Credit: